How to Start Xanomeline-Trospium in Outpatients With Schizophrenia
How should clinicians initiate and titrate xanomeline-trospium for outpatients with schizophrenia?
Adults with schizophrenia starting xanomeline-trospium in outpatient care need a practical plan that balances early symptom control with front-loaded gastrointestinal and anticholinergic tolerability. This workflow applies when XT is being used as monotherapy initiation in routine ambulatory practice, especially early in illness or when avoiding long-term dopamine-blocking burden is a priority.
-
Review medications and anticholinergic burden before starting
Perform a careful review of prescription drugs, over-the-counter medications, and dietary supplements before initiation. The panel emphasized reducing or eliminating unnecessary anticholinergic agents whenever possible, including diphenhydramine, and reviewing medications used for bladder control, COPD, Alzheimer’s disease, and Parkinson’s disease. XT may not be an appropriate option for men older than 50 years with a history of benign prostatic hyperplasia that may be associated with urinary retention.
-
Start XT at 50 mg/20 mg twice daily
Begin outpatient XT at the fixed starting dose of 50 mg/20 mg twice daily. The panel recommended that patients fill the prescription immediately after the visit so treatment can begin that same evening. All XT doses should be taken twice daily in the absence of food.
-
Co-prescribe ondansetron and counsel on fasted dosing
At initiation, prescribe a 14-day supply of ondansetron 4 mg to mitigate early nausea and vomiting. Patients should be instructed to re-dose ondansetron after 30 minutes if symptoms persist. Counsel clearly that XT must be taken on an empty stomach, because food can interfere with trospium chloride absorption and increase the likelihood of gastrointestinal side effects.
-
Reassess after 1 to 2 weeks
Assess efficacy and tolerability at the first follow-up after 1 to 2 weeks, ideally in person. Use this visit to monitor symptom improvement and emerging side effects, particularly nausea, vomiting, urinary retention, dry mouth, and constipation. The panel noted that efficacy in practice was often observed relatively quickly, sometimes within 1 week.
-
Increase to 100 mg/20 mg if tolerated
If the medication is well tolerated, increase the dose to 100 mg/20 mg twice daily. Continue follow-up according to the patient’s care plan, typically within 2 to 12 weeks. The panel noted that most patients stabilize on 100 mg/20 mg to 125 mg/30 mg twice daily.
-
Advance to 125 mg/30 mg only if needed and tolerated
If XT continues to be well tolerated and symptom control remains incomplete, increase further to 125 mg/30 mg twice daily. Some patients, particularly younger individuals or those earlier in their illness course, may achieve good control on 50 mg/20 mg, so full titration is not mandatory for every patient. Ongoing dose decisions should remain individualized to symptom management and tolerability.
Clinical Considerations
- These recommendations reflect expert consensus and early real-world experience rather than randomized head-to-head comparisons with standard antipsychotics.
- XT was studied as monotherapy in clinical development, so outpatient add-on practices discussed by the panel are based largely on clinical experience.
- Early gastrointestinal and anticholinergic adverse events tend to arise within the first 2 weeks and can affect adherence if not anticipated.
- The report notes limited long-term safety and functional outcome data, so implementation should be interpreted with appropriate caution.
Bottom Line
For outpatient XT initiation, start at 50 mg/20 mg twice daily without food, use prophylactic ondansetron, reassess at 1 to 2 weeks, and titrate stepwise based on tolerability and symptom response.
